ScreenPoint Medical Highlights Expanded Transpara Breast AI Suite at RSNA 2025

ScreenPoint Medical, an AI-powered technological company specializing in breast imaging to help detect breast cancer, showcased new advancements to its Transpara Breast AI Suite at RSNA 2025. The updated suite provides risk scoring, lesion detection and triage tools designed to help radiologists prioritize cases and identify cancers earlier, particularly in dense breast tissue. The company noted that Transpara is already in clinical use in more than 30 countries and is designed to integrate with existing PACS and reading workflows without major process changes.

Interest in breast imaging AI continues to grow as radiology groups face rising exam volumes and persistent staffing shortages. ScreenPoint’s long-standing focus on reader support and case triage positions Transpara as a mature option for clinics seeking incremental adoption rather than full workflow redesign. Another development included Transpara Risk that produces an image-based 5 year risk model for breast cancer along with Transpara Detection which is still being researched for investigational use only.

Posted by MedCloudInsider Editors on 12/01/2025